ovalbumin has been researched along with picric-acid* in 4 studies
4 other study(ies) available for ovalbumin and picric-acid
Article | Year |
---|---|
IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3.
IgG3, passively administered together with small proteins, induces enhanced primary humoral responses against these proteins. We previously found that, within 2 h of immunization, marginal zone (MZ) B cells capture IgG3-antigen complexes and transport them into splenic follicles and that this requires the presence of complement receptors 1 and 2. We have here investigated the localization of IgG3 anti-2, 4, 6-trinitrophenyl (TNP)/biotin-ovalbumin-TNP immune complexes in the follicles and the involvement of classical versus total complement activation in this process. The majority (50-90%) of antigen inside the follicles of mice immunized with IgG3-antigen complexes co-localized with the follicular dendritic cell (FDC) network. Capture of antigen by MZ B cells as well as antigen deposition on FDC was severely impaired in mice lacking C1q or C3, and lack of either C1q or C3 also impaired the ability of IgG3 to enhance antibody responses. Finally, IgG3 efficiently primed for a memory response against small proteins as well as against the large protein keyhole limpet hemocyanine. Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal; Antigens; B-Lymphocytes; Biotin; Complement Activation; Complement C1q; Complement C3; Dendritic Cells, Follicular; Hemocyanins; Hybridomas; Immunization, Passive; Immunoglobulin G; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Ovalbumin; Picrates; Receptors, Complement; Receptors, Complement 3d; Spleen; Whole-Body Irradiation | 2017 |
IgG3-mediated enhancement of the antibody response is normal in Fc gammaRI-deficient mice.
Antibodies, administered together with their specific antigen, can feedback-regulate antibody responses to this antigen. IgG1, IgG2a and IgG2b enhance antibody responses to soluble protein antigens. This effect is primarily mediated by FcRs as enhancement is impaired in FcR gamma-/- mice, reported to lack Fc gammaRI and Fc gammaRIII because of deletion of the common FcR gamma chain. Also IgG3 can enhance antibody responses. However, this effect is unperturbed in FcR gamma-/- mice but severely impaired in complement-depleted animals and in animals lacking complement receptor 1 and 2. Although this argues against involvement of Fc gammaRs, FcR gamma-/- mice may express one-fifth of the normal levels of Fc gammaRI and, in addition, Fc gammaRI has been suggested to bind IgG3. We re-investigated the dependence of IgG3-mediated enhancement on Fc gammaRs using a mouse strain selectively lacking Fc gammaRI and found that IgG3-mediated enhancement is completely normal. Unlike IgE and IgG2a, which are both thought to enhance T-cell proliferation via FcR-mediated antigen presentation, IgG3 was a poor enhancer of T-cell proliferation both in vivo and in vitro. These findings argue against a significant involvement of Fc gammaRs in IgG3-mediated enhancement of antibody responses and support our previous conclusion that complement plays a major role. Topics: Adoptive Transfer; Animals; Antibody Formation; Antigen Presentation; CD4-Positive T-Lymphocytes; Hemocyanins; Immunoglobulin G; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Transgenic; Ovalbumin; Picrates; Receptors, IgG; Vaccination | 2005 |
Selective requirement for CD40-CD154 in drug-induced type 1 versus type 2 responses to trinitrophenyl-ovalbumin.
CD154 is transiently expressed by activated T cells and interacts with CD40 on B cells, dendritic cells, macrophages, and monocytes. This costimulatory receptor-ligand couple seems decisive in Ag-driven immune responses but may be differentially involved in type 1 vs type 2 responses. We studied the importance of CD40-CD154 in both responses using the reporter Ag popliteal lymph node assay in which selectively acting drugs generate clearly polarized type 1 (streptozotocin) or type 2 (D-penicillamine, diphenylhydantoin) responses to a constant coinjected Ag in the same mouse strain. Treatment of mice with anti-CD154 reduced characteristic immunological parameters in type 2 responses (B and CD4(+) T cell proliferation, IgG1 and IgE Abs, and IL-4 secretion) and only slightly affected the type 1 response (small decrease in IFN-gamma production, influx of CD11c(+) and F4/80(+) cells, and prevention of architectural disruption of the lymph node, but no effect on IgG2a Ab and TNF-alpha secretion or B and CD4(+) T cell proliferation). The findings indicate that the CD40-CD154 costimulatory interaction is a prerequisite in drug-induced type 2 responses and is only marginally involved in type 1 responses. The observed expression patterns of CD80 and CD86 on different APC (B cells in type 2 and dendritic cells in type 1) may be responsible for this discrepancy. Topics: Animals; Antigens, CD; B7-1 Antigen; B7-2 Antigen; CD40 Antigens; CD40 Ligand; Dose-Response Relationship, Immunologic; Female; Haptens; Immune Sera; Injections, Subcutaneous; Intercellular Adhesion Molecule-1; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Ovalbumin; Penicillamine; Phenytoin; Picrates; Streptozocin; Th1 Cells; Th2 Cells | 2002 |
Specific immunosuppression by immunotoxins containing daunomycin.
Daunomycin, when conjugated with a targeting antigen by an acid-sensitive spacer, remains inactive at the intravascular pH of 7 but becomes active after cleavage within the acidic lysosomal environment of the target cell. This observation made it possible to construct cytocidal compounds that caused antigen-specific suppression of murine lymphocyte function. When daunomycin was coupled to the hapten conjugate of ovalbumin by an acid-sensitive cis-aconityl group, it caused hapten-specific impairment of immunocompetence in murine B lymphocytes in vitro and in vivo. Furthermore, the response by T lymphocytes to concanavalin A in vitro was selectively eliminated by a conjugate between daunomycin plus the acid-sensitive spacer and a monoclonal antibody specific for T cells. Topics: Animals; Autoimmune Diseases; Concanavalin A; Daunorubicin; Fluorescein; Fluoresceins; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred CBA; Nitrohydroxyiodophenylacetate; Ovalbumin; Picrates; Spleen; T-Lymphocytes | 1986 |